FDA Approves First Oral PCSK9 Inhibitor - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 2 min

Share

Objective:

To report the FDA approval of enlicitide (LIPFENDRA) for reducing LDL cholesterol in adults with hypercholesterolemia.

Approach:
  • Approval Details: Enlicitide is approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
  • Mechanism of Action: Enlicitide is a macrocyclic peptide that binds PCSK9, inhibiting its interaction with LDL receptors.
  • Clinical Trials: The approval was supported by phase 3 CORALreef Lipids and CORALreef HeFH trials, which were randomized, double-blind, and placebo-controlled.
Key Findings:
  • Enlicitide produced a 56% placebo-adjusted reduction in LDL-C at week 24 in CORALreef Lipids.
  • In CORALreef HeFH, enlicitide resulted in a 59% placebo-adjusted reduction in LDL-C at week 24.
  • Reductions in non–high-density lipoprotein cholesterol and apolipoprotein B were observed in both trials.
  • Adverse reactions were similar between enlicitide and placebo groups, with diarrhea and dizziness reported.
Interpretation:

Limitations:
  • The long-term effects on cardiovascular morbidity and mortality are still under investigation.
Conclusion:

Enlicitide is the first oral PCSK9 inhibitor approved by the FDA, providing a new option for LDL cholesterol management.

Sources:

Original Source(s)

FDA Approves First Oral PCSK9 Inhibitor

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Left ventricular longitudinal function and hyperkinetic profile: a new echo world to explore?

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.